News

NICE says AZ' ovarian cancer drug is too expensive


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

NICE says AZ' ovarian cancer drug is too expensive

Date: 03/06/2015


Preliminary guidelines from the National Institute for Health and Care Excellence have rejected the use of AstraZeneca’s ovarian cancer drug Lynparza by the National Health Service in England and Wales because it is too expensive, sparking dismay among cancer charities. 

Lynparza (olaparib) is approved as a targeted maintenance therapy for relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer in patients who carry BRCA1 or BRCA2 mutations and have previously undergone chemotherapy.

For more click here

Source: PharmaTimes

© Catalyst Innovation Portal 2019